alendronate has been researched along with Pericementitis in 32 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess sodium alendronate as a local adjunctive therapy for treating experimental periodontitis in male rats treated with chemotherapy." | 8.31 | Sodium alendronate is an effective adjunctive therapy for treating periodontitis in male rats treated with anticancer chemotherapy. ( de Almeida, JM; Ervolino, E; Fiorin, LG; Furquim, EMA; Matheus, HR; Novaes, VCN; Oliveira, FLP; Piovezan, BR, 2023) |
| "The study aimed to investigate the effect of alendronate (ALN) on the inhibition of alveolar bone loss in experimental periodontitis in Wistar rats." | 7.83 | Effect of alendronate on the progression of periodontitis induced by Porphyromonas gingivalis and Fusobacterium nucleatum: a study in rats. ( Crivellaro, V; Deliberador, TM; Giovanini, AF; Romito, GA; Storrer, CLM; Zielak, JC, 2016) |
| "This study assesses the effects of topical sodium alendronate (SA) as an adjuvant to the mechanical treatment of ligature-induced periodontitis in rats." | 7.81 | Adjuvant Therapy With Sodium Alendronate for the Treatment of Experimental Periodontitis in Rats. ( Bonfietti, LH; De Almeida, J; Ervolino, E; Faleiros, PL; Fernandes, LA; Garcia, VG; Martins, TM; Novaes, VC; Theodoro, LH, 2015) |
| "Sodium alendronate preserves alveolar bone resorption and has anti-inflammatory and antibacterial activities in experimental periodontitis." | 7.73 | Effect of sodium alendronate on alveolar bone resorption in experimental periodontitis in rats. ( Brito, GA; Carvalho, CB; Chaves, HV; Menezes, AM; Ribeiro, RA; Rocha, FA, 2005) |
| "The aim of this study was to evaluate the impact of alendronate (ALD) and estrogen (EST) therapies and their withdrawal on bone loss in experimental periodontitis in ovariectomized rats." | 7.72 | Alendronate may protect against increased periodontitis-related bone loss in estrogen-deficient rats. ( Casati, MZ; de Assis, DR; Duarte, PM; Nociti, FH; Sallum, AW; Sallum, EA, 2004) |
| "Experimental periodontitis was induced by repeated injection of Escherichia coli endotoxin (LPS) and 44 adult male Sprague-Dawley rats were divided into five study groups as follows: LPS, doxycycline + LPS, alendronate + LPS, doxycycline + alendronate + LPS, and saline control." | 7.72 | Effects of combined systemic administration of low-dose doxycycline and alendronate on endotoxin-induced periodontitis in rats. ( Atilla, G; Başkesen, A; Berdeli, AH; Buduneli, E; Buduneli, N; Türkoğlu, O; Vardar, S, 2004) |
| "This study tested the efficacy of alendronate, a bisphosphate, in reducing alveolar bone loss caused by experimental periodontitis in cynomolgus monkeys." | 7.69 | Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. ( Aufdemorte, TB; Brunsvold, M; Chaves, E; Kornman, KS; Quartuccio, H; Rodan, GA; Seedor, JG; Weinreb, M, 1994) |
| "Alendronate sodium is a potent inhibitor of bone resorption which has been effectively used to control osteolysis, and to treat Paget's disease and osteoporosis." | 6.71 | The effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial). ( El-Shinnawi, UM; El-Tantawy, SI, 2003) |
| "Periodontitis was induced by ligature in 60 Wistar rats randomized into the following groups: control (Group 1); PDT (Group 2); ALN 0." | 5.48 | Synergistic effect of photodynamic therapy and alendronate on alveolar bone loss in rats with ligature-induced periodontitis. ( Camacho-Alonso, F; Davia-Peña, RS; Martínez-Beneyto, Y; Merino, JJ; Tudela-Mulero, MR; Vilaplana-Vivo, C, 2018) |
| " Superior clinical treatment outcomes were shown when alendronate, rosuvastatin, boric acid, simvastatin, and tetracycline (only at 3 months) were utilized in furcation defects in conjunction with SRP alone or SRP + placebo." | 5.41 | Local drug delivery in the treatment of furcation defects in periodontitis: a systematic review. ( Chatzopoulos, GS; Koidou, VP; Tsalikis, L, 2023) |
| "Alveolar bone loss was evaluated morphometrically under a stereomicroscope." | 5.34 | Matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase-1, and laminin-5 gamma2 chain immunolocalization in gingival tissue of endotoxin-induced periodontitis in rats: effects of low-dose doxycycline and alendronate. ( Atilla, G; Buduneli, E; Buduneli, N; Sorsa, T; Vardar-Sengül, S; Wahlgren, J, 2007) |
| "Considering the emerging role of host-inflammatory response in treatment of periodontitis and the antiresorptive and osteostimulative properties of bisphosphonates, several studies are focusing on the role of alendronate as an addition to non-surgical periodontal therapy." | 5.22 | Added effect of 1% topical alendronate in intra-bony and inter-radicular defects as part of step II periodontal therapy: a systematic review with meta-analysis and trial sequential analysis. ( Arena, C; Caponio, VCA; Lo Muzio, L; Lo Russo, L; Troiano, G; Zhurakivska, K, 2022) |
| "To assess sodium alendronate as a local adjunctive therapy for treating experimental periodontitis in male rats treated with chemotherapy." | 4.31 | Sodium alendronate is an effective adjunctive therapy for treating periodontitis in male rats treated with anticancer chemotherapy. ( de Almeida, JM; Ervolino, E; Fiorin, LG; Furquim, EMA; Matheus, HR; Novaes, VCN; Oliveira, FLP; Piovezan, BR, 2023) |
| "The study aimed to investigate the effect of alendronate (ALN) on the inhibition of alveolar bone loss in experimental periodontitis in Wistar rats." | 3.83 | Effect of alendronate on the progression of periodontitis induced by Porphyromonas gingivalis and Fusobacterium nucleatum: a study in rats. ( Crivellaro, V; Deliberador, TM; Giovanini, AF; Romito, GA; Storrer, CLM; Zielak, JC, 2016) |
| " Surprisingly, the bone-targeted antiresorptives bis-enoxacin and alendronate inhibited increases in oxidative stress caused by periodontitis." | 3.81 | Periodontitis in rats induces systemic oxidative stress that is controlled by bone-targeted antiresorptives. ( Chukkapalli, SS; Holliday, LS; Kesavalu, L; Oktay, S; Rivera-Kweh, MF; Velsko, IM, 2015) |
| "This study assesses the effects of topical sodium alendronate (SA) as an adjuvant to the mechanical treatment of ligature-induced periodontitis in rats." | 3.81 | Adjuvant Therapy With Sodium Alendronate for the Treatment of Experimental Periodontitis in Rats. ( Bonfietti, LH; De Almeida, J; Ervolino, E; Faleiros, PL; Fernandes, LA; Garcia, VG; Martins, TM; Novaes, VC; Theodoro, LH, 2015) |
| "Sodium alendronate preserves alveolar bone resorption and has anti-inflammatory and antibacterial activities in experimental periodontitis." | 3.73 | Effect of sodium alendronate on alveolar bone resorption in experimental periodontitis in rats. ( Brito, GA; Carvalho, CB; Chaves, HV; Menezes, AM; Ribeiro, RA; Rocha, FA, 2005) |
| "The aim of the present study was to evaluate the effects of systemic administration of low-dose doxycycline and a bisphosphonate, alendronate, on serum levels of interleukin-1beta (IL-1beta), osteocalcin (OC), and C-reactive protein (CRP) in experimental periodontitis in rats." | 3.73 | Systemic low-dose doxycycline and alendronate administration and serum interleukin-1beta, osteocalcin, and C-reactive protein levels in rats. ( Atilla, G; Buduneli, E; Buduneli, N; Kardeşler, L; Kinane, DF; Lappin, D; Vardar-Sengül, S, 2005) |
| "The aim of this study was to evaluate the impact of alendronate (ALD) and estrogen (EST) therapies and their withdrawal on bone loss in experimental periodontitis in ovariectomized rats." | 3.72 | Alendronate may protect against increased periodontitis-related bone loss in estrogen-deficient rats. ( Casati, MZ; de Assis, DR; Duarte, PM; Nociti, FH; Sallum, AW; Sallum, EA, 2004) |
| "Experimental periodontitis was induced by repeated injection of Escherichia coli endotoxin (LPS) and 44 adult male Sprague-Dawley rats were divided into five study groups as follows: LPS, doxycycline + LPS, alendronate + LPS, doxycycline + alendronate + LPS, and saline control." | 3.72 | Effects of combined systemic administration of low-dose doxycycline and alendronate on endotoxin-induced periodontitis in rats. ( Atilla, G; Başkesen, A; Berdeli, AH; Buduneli, E; Buduneli, N; Türkoğlu, O; Vardar, S, 2004) |
| "This study tested the efficacy of alendronate, a bisphosphate, in reducing alveolar bone loss caused by experimental periodontitis in cynomolgus monkeys." | 3.69 | Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. ( Aufdemorte, TB; Brunsvold, M; Chaves, E; Kornman, KS; Quartuccio, H; Rodan, GA; Seedor, JG; Weinreb, M, 1994) |
| "Periodontal disease is characterized by periodontal bone loss." | 2.73 | Efficacy of bisphosphonates for the control of alveolar bone loss in periodontitis. ( Cizza, G; Genco, R; Jeffcoat, MK; Lombardi, A; Shih, WJ, 2007) |
| "Alendronate sodium is a potent inhibitor of bone resorption which has been effectively used to control osteolysis, and to treat Paget's disease and osteoporosis." | 2.71 | The effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial). ( El-Shinnawi, UM; El-Tantawy, SI, 2003) |
| "Alendronate (ALN) is an aminobisphosphonate commonly used for osteoporosis in postmenopausal women." | 2.70 | Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial. ( Garay-Sevilla, ME; Malacara, JM; Nava, LE; Rocha, M; Sánchez-Márin, F; Vázquez de la Torre, C, 2001) |
| "Because the severity of alveolar bone loss increases with age, it has long been hypothesized that it may, in part, be related to systemic conditions that also predispose the patient to osteoporosis/osteopenia." | 2.40 | Osteoporosis: a possible modifying factor in oral bone loss. ( Jeffcoat, MK, 1998) |
| "Periodontitis was induced by ligature in 60 Wistar rats randomized into the following groups: control (Group 1); PDT (Group 2); ALN 0." | 1.48 | Synergistic effect of photodynamic therapy and alendronate on alveolar bone loss in rats with ligature-induced periodontitis. ( Camacho-Alonso, F; Davia-Peña, RS; Martínez-Beneyto, Y; Merino, JJ; Tudela-Mulero, MR; Vilaplana-Vivo, C, 2018) |
| "Periodontitis was induced by ligature around the upper second molar in 36 male Wistar rats (± 200 g)." | 1.38 | Effect of alendronate on bone-specific alkaline phosphatase on periodontal bone loss in rats. ( Dutra, CS; Goes, P; Lima, AP; Lima, V; Melo, IM, 2012) |
| "Pretreatment with alendronate augmented IL-1beta, but not TNFalpha, production by macrophages infected with P." | 1.35 | Alendronate augments interleukin-1beta release from macrophages infected with periodontal pathogenic bacteria through activation of caspase-1. ( Deng, X; Endo, Y; Kiyoura, Y; Tamai, R, 2009) |
| "Alveolar bone loss was evaluated morphometrically under a stereomicroscope." | 1.34 | Matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase-1, and laminin-5 gamma2 chain immunolocalization in gingival tissue of endotoxin-induced periodontitis in rats: effects of low-dose doxycycline and alendronate. ( Atilla, G; Buduneli, E; Buduneli, N; Sorsa, T; Vardar-Sengül, S; Wahlgren, J, 2007) |
| "Sixty-two (52." | 1.33 | Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. ( Broumand, V; Fortin, M; Marx, RE; Sawatari, Y, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (12.50) | 18.2507 |
| 2000's | 14 (43.75) | 29.6817 |
| 2010's | 11 (34.38) | 24.3611 |
| 2020's | 3 (9.38) | 2.80 |
| Authors | Studies |
|---|---|
| Arena, C | 1 |
| Caponio, VCA | 1 |
| Zhurakivska, K | 1 |
| Lo Russo, L | 1 |
| Lo Muzio, L | 1 |
| Troiano, G | 1 |
| Chatzopoulos, GS | 1 |
| Koidou, VP | 1 |
| Tsalikis, L | 1 |
| Oliveira, FLP | 1 |
| Matheus, HR | 1 |
| Ervolino, E | 2 |
| Novaes, VCN | 1 |
| Piovezan, BR | 1 |
| Furquim, EMA | 1 |
| Fiorin, LG | 1 |
| de Almeida, JM | 1 |
| Camacho-Alonso, F | 1 |
| Davia-Peña, RS | 1 |
| Vilaplana-Vivo, C | 1 |
| Tudela-Mulero, MR | 1 |
| Merino, JJ | 1 |
| Martínez-Beneyto, Y | 1 |
| Carvalho Dutra, B | 1 |
| Oliveira, AMSD | 1 |
| Oliveira, PAD | 1 |
| Miranda Cota, LO | 1 |
| Silveira, JO | 1 |
| Costa, FO | 1 |
| Oktay, S | 1 |
| Chukkapalli, SS | 1 |
| Rivera-Kweh, MF | 1 |
| Velsko, IM | 1 |
| Holliday, LS | 1 |
| Kesavalu, L | 2 |
| Moreira, MM | 1 |
| Bradaschia-Correa, V | 1 |
| Marques, ND | 1 |
| Ferreira, LB | 1 |
| Arana-Chavez, VE | 1 |
| De Almeida, J | 1 |
| Bonfietti, LH | 1 |
| Novaes, VC | 1 |
| Theodoro, LH | 1 |
| Fernandes, LA | 1 |
| Martins, TM | 1 |
| Faleiros, PL | 1 |
| Garcia, VG | 1 |
| Storrer, CLM | 1 |
| Deliberador, TM | 1 |
| Giovanini, AF | 1 |
| Crivellaro, V | 1 |
| Zielak, JC | 1 |
| Romito, GA | 1 |
| Deng, X | 1 |
| Tamai, R | 1 |
| Endo, Y | 1 |
| Kiyoura, Y | 1 |
| Grey, A | 1 |
| Aguirre, JI | 1 |
| Akhter, MP | 1 |
| Kimmel, DB | 1 |
| Pingel, JE | 1 |
| Williams, A | 1 |
| Jorgensen, M | 1 |
| Wronski, TJ | 1 |
| Goes, P | 1 |
| Melo, IM | 1 |
| Dutra, CS | 1 |
| Lima, AP | 1 |
| Lima, V | 1 |
| Price, U | 1 |
| Le, HO | 1 |
| Powell, SE | 1 |
| Schmid, MJ | 1 |
| Marx, DB | 1 |
| Zhang, Y | 1 |
| Wang, D | 1 |
| Narayana, N | 1 |
| Reinhardt, RA | 1 |
| Hasegawa, T | 1 |
| Ri, S | 1 |
| Umeda, M | 1 |
| Komatsubara, H | 1 |
| Kobayashi, M | 1 |
| Shigeta, T | 1 |
| Yoshitomi, I | 1 |
| Ikeda, H | 1 |
| Shibuya, Y | 1 |
| Asahina, I | 1 |
| Komori, T | 1 |
| Tenenbaum, HC | 1 |
| Shelemay, A | 1 |
| Girard, B | 1 |
| Zohar, R | 1 |
| Fritz, PC | 1 |
| El-Shinnawi, UM | 1 |
| El-Tantawy, SI | 1 |
| Duarte, PM | 1 |
| de Assis, DR | 1 |
| Casati, MZ | 1 |
| Sallum, AW | 1 |
| Sallum, EA | 1 |
| Nociti, FH | 1 |
| Buduneli, E | 3 |
| Vardar, S | 1 |
| Buduneli, N | 3 |
| Berdeli, AH | 1 |
| Türkoğlu, O | 1 |
| Başkesen, A | 1 |
| Atilla, G | 3 |
| Lane, N | 1 |
| Armitage, GC | 1 |
| Loomer, P | 1 |
| Hsieh, S | 1 |
| Majumdar, S | 1 |
| Wang, HY | 1 |
| Jeffcoat, M | 1 |
| Munoz, T | 1 |
| Marx, RE | 1 |
| Sawatari, Y | 1 |
| Fortin, M | 1 |
| Broumand, V | 1 |
| Menezes, AM | 1 |
| Rocha, FA | 1 |
| Chaves, HV | 1 |
| Carvalho, CB | 1 |
| Ribeiro, RA | 1 |
| Brito, GA | 1 |
| Vardar-Sengül, S | 2 |
| Kardeşler, L | 1 |
| Lappin, D | 1 |
| Kinane, DF | 1 |
| Wahlgren, J | 1 |
| Sorsa, T | 1 |
| Jeffcoat, MK | 3 |
| Cizza, G | 1 |
| Shih, WJ | 1 |
| Genco, R | 1 |
| Lombardi, A | 1 |
| Xiong, H | 1 |
| Peng, B | 1 |
| Wei, L | 1 |
| Zhang, X | 1 |
| Wang, L | 1 |
| Reddy, MS | 1 |
| Weatherford, TW | 1 |
| Smith, CA | 1 |
| West, BD | 1 |
| Jacks, TM | 1 |
| Weinreb, M | 1 |
| Quartuccio, H | 1 |
| Seedor, JG | 1 |
| Aufdemorte, TB | 2 |
| Brunsvold, M | 1 |
| Chaves, E | 1 |
| Kornman, KS | 2 |
| Rodan, GA | 1 |
| Rocha, M | 1 |
| Nava, LE | 1 |
| Vázquez de la Torre, C | 1 |
| Sánchez-Márin, F | 1 |
| Garay-Sevilla, ME | 1 |
| Malacara, JM | 1 |
| Ciancio, SG | 1 |
| Brunsvold, MA | 1 |
| Chaves, ES | 1 |
| Wood, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigation of the Effects of Bisphosphonate on the Gingival Crevicular Fluid Levels of Sclerostin and the DKK-1 in Individuals With Postmenopausal Osteoporosis With Periodontal Changes[NCT04149405] | Phase 4 | 43 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Effect of Periodontal Therapy and Bisphosphonates on Gingival Crevicular Fluid Levels of Nuclear Factor- κb Ligand (RANKL) and Osteoprotegerin in Postmenopausal Osteoporosis: Results of a 12-Month Study[NCT02808988] | Phase 4 | 47 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| The Effect of Orally Administered Bisphosphonates in the Treatment of Osteoporosis on the Alveolar Bone Using Panoramic and Cone-Beam CT Imaging: A Case-control Study[NCT02115490] | 60 participants (Actual) | Observational | 2014-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
levels of dickkopf-related protein-1 in 12th month (NCT04149405)
Timeframe: 12 months
| Intervention | ng/ml (Mean) |
|---|---|
| Group A | 3440.67 |
| Group B | 3203.802 |
| Group C | 2490.553 |
| Group D | 4269.39 |
levels of dickkopf-related protein-1 in 6th month (NCT04149405)
Timeframe: 6 months
| Intervention | ng/ml (Mean) |
|---|---|
| Group A | 3358.265 |
| Group B | 1963.185 |
| Group C | 3263.665 |
| Group D | 4269.39 |
levels of sclerostin in 12th month (NCT04149405)
Timeframe: 12 month
| Intervention | ng/ml (Mean) |
|---|---|
| Group A | 1702.265 |
| Group B | 1347.330 |
| Group C | 1114.988 |
| Group D | 2131.87 |
levels of sclerostin in 6th month (NCT04149405)
Timeframe: 6 months
| Intervention | ng/ml (Mean) |
|---|---|
| Group A | 1389.177 |
| Group B | 1085.405 |
| Group C | 1596.585 |
| Group D | 2131.87 |
5 reviews available for alendronate and Pericementitis
| Article | Year |
|---|---|
Added effect of 1% topical alendronate in intra-bony and inter-radicular defects as part of step II periodontal therapy: a systematic review with meta-analysis and trial sequential analysis.
Topics: Alendronate; Alveolar Bone Loss; Diphosphonates; Humans; Periodontal Attachment Loss; Periodontitis | 2022 |
Local drug delivery in the treatment of furcation defects in periodontitis: a systematic review.
Topics: Alendronate; Dental Scaling; Furcation Defects; Humans; Periodontitis; Root Planing; Rosuvastatin Ca | 2023 |
Bisphosphonates and periodontics: potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses.
Topics: Alendronate; Alveolar Bone Loss; Animals; Bone Density; Bone Regeneration; Diphosphonates; Etidronic | 2002 |
Osteoporosis: a possible modifying factor in oral bone loss.
Topics: Alendronate; Alveolar Bone Loss; Bone Density; Estrogen Replacement Therapy; Female; Humans; Male; M | 1998 |
Systemic medications: clinical significance in periodontics.
Topics: Alendronate; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroida | 2002 |
5 trials available for alendronate and Pericementitis
| Article | Year |
|---|---|
Effects of topical application of 1% sodium alendronate gel in the surgical treatment of periodontal intrabony defects: A 6-month randomized controlled clinical trial.
Topics: Alendronate; Alveolar Bone Loss; Follow-Up Studies; Guided Tissue Regeneration, Periodontal; Humans; | 2019 |
The effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial).
Topics: Absorptiometry, Photon; Adult; Alendronate; Alveolar Bone Loss; Alveolar Process; Bone Density; Dent | 2003 |
Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study.
Topics: Alendronate; Alveolar Bone Loss; Analysis of Variance; Chemotherapy, Adjuvant; Dental Scaling; Dipho | 2005 |
Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study.
Topics: Alendronate; Alveolar Bone Loss; Analysis of Variance; Chemotherapy, Adjuvant; Dental Scaling; Dipho | 2005 |
Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study.
Topics: Alendronate; Alveolar Bone Loss; Analysis of Variance; Chemotherapy, Adjuvant; Dental Scaling; Dipho | 2005 |
Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study.
Topics: Alendronate; Alveolar Bone Loss; Analysis of Variance; Chemotherapy, Adjuvant; Dental Scaling; Dipho | 2005 |
Efficacy of bisphosphonates for the control of alveolar bone loss in periodontitis.
Topics: Adult; Aged; Alendronate; Alveolar Bone Loss; Alveolar Process; Analysis of Variance; Bone Density; | 2007 |
Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial.
Topics: Alendronate; Alveolar Bone Loss; Alveolar Process; Biomarkers; Bone Resorption; Case-Control Studies | 2001 |
22 other studies available for alendronate and Pericementitis
| Article | Year |
|---|---|
Sodium alendronate is an effective adjunctive therapy for treating periodontitis in male rats treated with anticancer chemotherapy.
Topics: Alendronate; Alveolar Bone Loss; Animals; Dental Scaling; Fluorouracil; Male; Osteocalcin; Periodont | 2023 |
Synergistic effect of photodynamic therapy and alendronate on alveolar bone loss in rats with ligature-induced periodontitis.
Topics: Alendronate; Alveolar Bone Loss; Animals; Bone Density; Disease Models, Animal; Drug Combinations; D | 2018 |
Periodontitis in rats induces systemic oxidative stress that is controlled by bone-targeted antiresorptives.
Topics: Alendronate; Animals; Anti-Bacterial Agents; Antioxidants; Bacteroidaceae Infections; Bacteroides In | 2015 |
Ultrastructural and immunohistochemical study of the effect of sodium alendronate in the progression of experimental periodontitis in rats.
Topics: Alendronate; Alveolar Process; Animals; Dental Papilla; Disease Progression; Gingiva; Male; Microsco | 2014 |
Adjuvant Therapy With Sodium Alendronate for the Treatment of Experimental Periodontitis in Rats.
Topics: Alendronate; Alveolar Process; Animals; Apoptosis; Bone Density Conservation Agents; Caspase 3; Comb | 2015 |
Effect of alendronate on the progression of periodontitis induced by Porphyromonas gingivalis and Fusobacterium nucleatum: a study in rats.
Topics: Alendronate; Alveolar Bone Loss; Animals; Disease Progression; Fusobacterium nucleatum; Male; Period | 2016 |
Alendronate augments interleukin-1beta release from macrophages infected with periodontal pathogenic bacteria through activation of caspase-1.
Topics: Alendronate; Animals; Bacteroidaceae; Bone Density Conservation Agents; Caspase 1; Clodronic Acid; D | 2009 |
Teriparatide for bone loss in the jaw.
Topics: Alendronate; Bone Density Conservation Agents; Bone Regeneration; Combined Modality Therapy; Humans; | 2010 |
Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis.
Topics: Alendronate; Animals; Apoptosis; Bisphosphonate-Associated Osteonecrosis of the Jaw; Cell Count; Dip | 2012 |
Effect of alendronate on bone-specific alkaline phosphatase on periodontal bone loss in rats.
Topics: Alendronate; Alkaline Phosphatase; Alveolar Bone Loss; Alveolar Process; Analysis of Variance; Anima | 2012 |
Effects of local simvastatin-alendronate conjugate in preventing periodontitis bone loss.
Topics: Alendronate; Alveolar Bone Loss; Animals; beta-Cyclodextrins; Bone Density Conservation Agents; Drug | 2013 |
The observational study of delayed wound healing after tooth extraction in patients receiving oral bisphosphonate therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Antibiotic Prophylaxis; Bisphosph | 2013 |
Alendronate may protect against increased periodontitis-related bone loss in estrogen-deficient rats.
Topics: Alendronate; Alkaline Phosphatase; Alveolar Bone Loss; Alveolar Process; Animals; Dental Plaque Inde | 2004 |
Effects of combined systemic administration of low-dose doxycycline and alendronate on endotoxin-induced periodontitis in rats.
Topics: Alendronate; Alveolar Bone Loss; Animals; Anti-Bacterial Agents; Dinoprost; Dinoprostone; Doxycyclin | 2004 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breas | 2005 |
Effect of sodium alendronate on alveolar bone resorption in experimental periodontitis in rats.
Topics: Alendronate; Alveolar Bone Loss; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Bone Dens | 2005 |
Systemic low-dose doxycycline and alendronate administration and serum interleukin-1beta, osteocalcin, and C-reactive protein levels in rats.
Topics: Alendronate; Alveolar Bone Loss; Animals; Anti-Bacterial Agents; Bone Density Conservation Agents; C | 2005 |
Matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase-1, and laminin-5 gamma2 chain immunolocalization in gingival tissue of endotoxin-induced periodontitis in rats: effects of low-dose doxycycline and alendronate.
Topics: Alendronate; Alveolar Bone Loss; Animals; Anti-Bacterial Agents; Bone Density Conservation Agents; C | 2007 |
Effect of an estrogen-deficient state and alendronate therapy on bone loss resulting from experimental periapical lesions in rats.
Topics: Alendronate; Alveolar Bone Loss; Animals; Bone Density Conservation Agents; Estrogens; Female; Injec | 2007 |
Alendronate treatment of naturally-occurring periodontitis in beagle dogs.
Topics: Alendronate; Alveolar Bone Loss; Analysis of Variance; Animals; Diphosphonates; Disease Models, Anim | 1995 |
Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys.
Topics: Alendronate; Alveolar Bone Loss; Animals; Bone Density; Diphosphonates; Macaca fascicularis; Mandibu | 1994 |
Effects of a bisphosphonate on experimental periodontitis in monkeys.
Topics: Alendronate; Alveolar Bone Loss; Animals; Bone Density; Dental Plaque Index; Diphosphonates; Macaca | 1992 |